Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis

BJU International

Volumn 109, Issue 3, 2012, Pages 394-400

  Izumi, Kouji ^a   Mizokami, Atsushi ^a   Itai, Shingo ^a   Shima, Takashi ^a   Shigehara, Kazuyoshi ^a   Miwa, Sotaro ^a   Maeda, Yuji ^a   Konaka, Hiroyuki ^a   Koh, Eitetsu ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

bone metastasis; bone turnover marker; prostate cancer; skeletal related events; zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTINEOPLASTIC AGENT; CARBOXY TERMINAL TELOPEPTIDE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; JAW OSTEONECROSIS; MALE; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CANCER; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84855970267     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10192.x     Document Type: Article

References (25)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
2. Jemal A, Siegel R, Ward E,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
3. Petrylak DP,. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999; 54 (Suppl.): 30-5
4. Oh WK,. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88 (Suppl.): 3015-21 (Pubitemid 30413185)
5. Rubin MA, Putzi M, Mucci N, et al,. Rapid ('warm') autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000; 6: 1038-45 (Pubitemid 30159365)
6. Denis L,. Prostate cancer. Primary hormonal treatment. Cancer 1993; 71 (Suppl.): 1050-8 (Pubitemid 23049631)
7. Scher HI, Chung LW,. Bone metastases: improving the therapeutic index. Semin Oncol 1994; 21: 630-56 (Pubitemid 24329140)
8. Saad F, Gleason DM, Murray R, et al,. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68
9. Lein M, Wirth M, Miller K, et al,. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007; 52: 1381-7 (Pubitemid 47445973)
10. Soloway MS, Hardeman SW, Hickey D, et al,. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202 (Pubitemid 18023133)
11. Coleman RE,. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002; 94: 2521-33 (Pubitemid 34478064)
12. Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman I, Rubens RD,. Biochemical prediction of response of bone metastases to treatment. Br J Cancer 1988; 58: 205-10
13. Berruti A, Dogliotti L, Gorzegno G, et al,. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999; 45: 1240-7 (Pubitemid 29424263)
14. Coleman RE, Major P, Lipton A, et al,. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-35 (Pubitemid 46223998)
15. Lipton A, Cook R, Saad F, et al,. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201 (Pubitemid 351976401)
16. Mountzios G, Terpos E, Syrigos K, et al,. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonatezoledronic acid. Transl Res 2010; 155: 247-55
17. Brown JE, Cook RJ, Major P, et al,. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69
18. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE,. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 2010; 123: 767-79
19. Lein M, Miller K, Wirth M, et al,. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 2009; 69: 624-32
20. Casimiro S, Guise TA, Chirgwin J,. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310: 71-81
21. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H,. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171: 679-83 (Pubitemid 38090455)
22. Hirano D, Minei S, Kishimoto Y, et al,. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int 2005; 75: 43-9 (Pubitemid 41022593)
23. Nishimura K, Nonomura N, Satoh E, et al,. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001; 93: 1739-46 (Pubitemid 33130263)
24. Tannock IF, de Wit R, Berry WR, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
25. Petrylak DP, Tangen CM, Hussain MH, et al,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 (Pubitemid 39315318)